BP
NVO

BNP Paribas’s Novo Nordisk NVO Stock Holding History

BNP Paribas’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$13.9K – 368
2025
Q1 		$13.9K Buy
+200
New +$16.5K ﹤0.01% 304

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BNP Paribas's NVO Position: Q2 2025 in Review

BNP Paribas sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 200 shares — an estimated $13.9K sold.

BNP Paribas first reported a position in NVO in Q1 2025 and held it in 1 quarter. The position peaked at $13.9K in Q1 2025. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • BNP Paribas reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • BNP Paribas sold 200 Novo Nordisk shares in Q2 2025, an estimated $13.9K.
  • BNP Paribas first reported a position in Novo Nordisk in Q1 2025 and held it in 1 quarter.
  • BNP Paribas's Novo Nordisk position peaked at $13.9K in Q1 2025.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on BNP Paribas's 13F filing for Q2 2025, filed 14 Aug 2025.